BioEclipse Therapeutics

BioEclipse Therapeutics is pioneering a novel approach to treating solid tumors by combining innate and adaptive immune mechanisms within a single, engineered cell therapy. The company has two primary programs: an autologous therapy (CRX100) in Phase 1b trials and an IND-ready allogeneic, off-the-shelf therapy (CRX200). Focused on the significant unmet need in refractory solid tumors, which represent 90% of cancers, BioEclipse aims to overcome the high failure rates of current immunotherapies in this space with its potentially transformative and cost-effective platform.

Proprietary cell therapy platform engineering living immune cells to harness both innate and adaptive immunity to attack solid tumors. Supports development of both autologous and allogeneic (off-the-shelf) therapies.

BioEclipse competes in the crowded and rapidly evolving field of solid tumor immunotherapy, facing competition from large pharma checkpoint inhibitors, targeted therapies, and a growing number of biotech companies developing next-gen cell therapies (CAR-T, TCR, NK cells), oncolytic viruses, and other immune modulators. Differentiation relies on its unique multi-mechanism platform and off-the-shelf approach.